Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for SAB-142 in Stage 3 Type 1 Diabetes (T1D). The expected timing is based on the latest available company guidance and may change.
SAFEGUARD trial. 12/17/25:- Ph1 data confirmed favorable safety. 12/18/25:- First patient dosed; global enrollment ongoing. 03/09/26:- Dosing progressing; enrollment completion by YE 2026; topline data in H2 2027. 04/15/26:- SAFEGUARD Ph2b enrolling; IDS Congress Apr 21-22, 2026 presents C-peptide/mechanistic data; topline 2H 2027. 04/22/26:- IDS 2026 Ph1 HUMAN data showed C-peptide preservation and better CGM control. SAFEGUARD topline reiterated H2 2027. 05/12/26:- SAFEGUARD Ph2b Part A fully enrolled, Part B enrolling; FDA allows C-peptide AUC surrogate endpoint; topline 2H 2027. 05/29/26:- ADA Jun 5 and FOCIS Jun 10, 2026 presentations. SAFEGUARD topline reiterated H2 2027. 07/07/26:- PRISE-hATG investigator-led study announced for Stage 3 T1D 100 days to 2 years post-diagnosis. 08/06/26:- SAFEGUARD has 60-plus sites; enrollment completion Q4 2026 and topline H2 2027 remain on track.
Verification
Confirm timing and program details against the company announcement or filing.